In animal models of Alzheimer’s disease, RARα agonists have been demonstrated to decrease congenital neuroinflammation, enhance phagocytosis, and decrease neuropathology [32,33,34,35]. This evidence concerns the gene RARA and early-onset autosomal dominant Alzheimer disease.